KBC Group NV Sells 10,826 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

KBC Group NV reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 77,537 shares of the company's stock after selling 10,826 shares during the quarter. KBC Group NV owned about 0.10% of IDEXX Laboratories worth $32,562,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. K.J. Harrison & Partners Inc bought a new position in shares of IDEXX Laboratories in the 1st quarter worth $630,000. Little House Capital LLC acquired a new position in IDEXX Laboratories during the first quarter worth $589,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in IDEXX Laboratories by 0.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 199,390 shares of the company's stock worth $83,734,000 after buying an additional 940 shares during the last quarter. Westwind Capital lifted its stake in shares of IDEXX Laboratories by 2.6% in the first quarter. Westwind Capital now owns 45,836 shares of the company's stock valued at $19,249,000 after buying an additional 1,174 shares in the last quarter. Finally, Villere ST Denis J & Co. LLC grew its holdings in shares of IDEXX Laboratories by 0.6% during the first quarter. Villere ST Denis J & Co. LLC now owns 62,805 shares of the company's stock valued at $26,375,000 after buying an additional 363 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IDXX. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Leerink Partners raised their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Finally, Stifel Nicolaus upped their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $5.02 during trading hours on Monday, hitting $536.34. 471,085 shares of the company's stock traded hands, compared to its average volume of 645,066. The company has a fifty day simple moving average of $499.01 and a 200-day simple moving average of $450.94. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. The stock has a market capitalization of $43.13 billion, a price-to-earnings ratio of 49.57, a PEG ratio of 3.88 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $536.87.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.71 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.